This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Impacting 25 million people globally [1], deep venous disease results from venous thromboembolism, a condition that occurs when a bloodclot forms in the vein [2]. Ultimately, the new device promises to enable excellent clinical outcomes and drive significant quality of life improvements.”
While it’s well-known that mental health issues like anxiety and depression can profoundly impact one’s quality of life, what’s often overlooked is their potential to affect physical health, particularly the heart. Research has shown that individuals with depression are more likely to develop heart disease.
The research is funded by a four-year, $7.8 million grant awarded to Georgia Tech by the United States Department of Defense Congressionally Directed Medical Research Programs (CDMRP) as part of the agency’s call for the development of less invasive treatment technologies for cardiovascular conditions associated with cardiomyopathy.
Researchers found no significant difference between groups in terms of a composite of death, disabling stroke or rehospitalization for heart failure—which occurred in 9.4% Researchers found no significant difference between groups in terms of a composite of death, disabling stroke or rehospitalization for heart failure—which occurred in 9.4%
Furthermore, resistance training appears to improve arterial stiffness and endothelial function — two important prognostic indicators — and reduce inflammation (C-reactive protein) and bloodclotting risk.
Furthermore, resistance training appears to improve arterial stiffness and endothelial function — two important prognostic indicators — and reduce inflammation (C-reactive protein) and bloodclotting risk.
In the same sense the best medications to take are those that are both safe but also in the long term offer a substantial return in terms of either improving quality of life and/or an improvement in length of life. If we think about it, this is how we decide to invest our money in a bank. We rarely ever ask ‘how good’.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content